Our data validate MET/FAK signalling as a mechanism that enables CDK4/6-independent CDK2 activation and cell cycle transit, and we provide evidence for the utility of MET or FAK inhibition as a means to improve tumour response to CDK4/6 inhibition in vivo. The gene discussed is CDK2; the disease is neoplasm.